Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum

WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24. Entasis will present 11 posters with one oral presentation highlighting ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against Pseudomonas aeruginosa. Presentations will also include updates on SUL-DUR, a β-lactam/β-lactamase inhibitor currently in a Phase 3 registrational clinical trial to treat infections caused by carbapenem-resistant Acinetobacter baumannii, and ETX0282CPDP, an oral β-lactam/β-lactamase inhibitor being developed to treat multidrug-resistant Gram-negative pathogens, including those caused by extended-spectrum β-lactamases (ESBLs) and carbapenem-resistant Enterobacteriaceae (CRE).

The details of the presentations are as follows:

SUL-DUR Presentations:

Poster: Outer membrane permeability and efflux do not limit antibacterial activity of sulbactam-durlobactam in Acinetobacter baumannii
Session: AAR09 Pharmacological Studies of Investigational Agents Pre-NDA
Poster Number: WMF21-0322

Poster: Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of Sulbactam-Durlobactam
Session: AAR09 Pharmacological Studies of Investigational Agents Pre-NDA
Poster Number: WMF21-0325

Poster: Sulbactam-Durlobactam MIC and Disk Diffusion Quality Control Ranges Using a CLSI M23-A4 Study Design
Session: AAR09 Pharmacological Studies of Investigational Agents Pre-NDA
Poster Number: WMF21-0326

ETX0282CPDP Presentation:

Poster: The β-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against recent (2017-2019), geographically diverse drug-resistant Enterobacterales isolates
Session: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)
Poster Number: WMF21-0290

ETX0462 Presentations:

Oral Presentation: The Discovery of the Novel Diazabicyclooctane (DBO) ETX0462: A Single Antibacterial Agent to Treat Gram-negative Infections, Including MDR Pseudomonas aeruginosa
Session: AAR107 New Agents Discovery Summary Session: Early New Antimicrobial Agents
Date and Time: Monday, June 21, 2021, 11:00am-12:30 pm

Poster: ETX0462 Inhibits Penicillin-Binding Protein 3 of Pseudomonas aeruginosa and Escherichia coli
Session: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)
Poster Number: WMF21-0287

Poster: ETX0462 is a Novel PBP Inhibitor with Potent Activity against Recent, Global, Gram-Negative, Clinical Isolates
Session: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)
Poster Number: WMF21-0293

Poster: The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Retains Potent Antibacterial Activity Across Isogenic Panels of Gram-negative Resistant Determinants
Session: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)
Poster Number: WMF21-0288

Poster: ETX0462, a Novel Non β-lactam PBP Inhibitor, Is Bactericidal Against Gram negative pathogens with a Low Propensity for Mutant Generation
Session: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)
Poster Number: WMF21-0286

Poster: Evaluation of the Pharmacokinetics/Pharmacodynamics (PK/PD) of the Novel Diazabicyclooctane (DBO) ETX0462 Against Pseudomonas aeruginosa Infections, Including MDR Strains
Session: AAR07 Antimicrobial Pharmacokinetics and Pharmacodynamics
Poster Number: WMF21-0292

Poster: The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Has Potent Activity Against Biothreat Pathogens In Vitro and In Vivo
Session: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)
Date and Time: WMF21-0312

About Entasis Therapeutics Inc.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.

Company Contact		Investor Contact
Kyle Dow		Bruce Mackle
Entasis Therapeutics		LifeSci Advisors
(781) 810-0114		(929) 469-3859
kyle.dow@entasistx.com		bmackle@lifesciadvisors.com

Source: Entasis Therapeutics Holdings Inc.

READ FULL TEXT

Michael N. Dudley, Pharm.D.

President and Chief Executive Officer
Qpex Biopharma, Inc.

Dr. Dudley has over 30 years of experience in antiinfective drug research, development, and commercialization. In 2018, he co-founded Qpex Biopharma which raised $33M in Series A financing and acquired the preclinical infectious disease programs from The Medicines Company. He has overseen the development and regulatory approval of 3 antibiotics, most recently a beta-lactamase inhibitor combination product from a new chemical class (vaborbactam) discovered in the company laboratories. The antibiotic product Vabomere™ advanced from discovery to FDA approval in 2017 in less than 8 years. He lead the negotiation for multiple contracts from public-private partnerships (e.g., BARDA of the US Government; Innovative Medicines Initiative for the EU) for a combined total of over $190 million funding to advance antimicrobial agents in development in the US and Europe. Prior to co-founding Qpex, he was Chief Scientific Officer and co-founder of Rempex Pharmaceuticals that was acquired by the Medicines Company (MDCO) in 2013, where he remained as the co-leader of the Infectious Disease Business Unit of MDCO. Prior to Rempex, he held VP/SVP/CSO positions of increasing responsibility at the biotech companies Mpex Pharmaceuticals (acquired by Aptalis in 2011), Diversa Corporation, and Microcide Pharmaceuticals. Prior to his career in pharmaceutical industry, he held full-time academic appointments that included Professor of Pharmacy and Chairman of the Department of Pharmacy Practice at the University of Rhode Island College of Pharmacy (URI), and Adjunct Professor of Medicine, Brown University School of Medicine at Roger Williams Medical Center in Providence, RI. As an academic researcher, he conducted preclinical and clinical research in antibacterial, antifungal, and antiviral agents, including pioneering work on PK-PD approaches for several classes of antiinfectives. Dr. Dudley has published over 130 scientific papers and book chapters describing the evaluation and clinical use of antiinfective agents and treatment of infectious diseases. He has served as an invited speaker at several FDA and EMA workshops, international meetings on infectious diseases, and advisor to several companies. He has served as an Editor for the journal Antimicrobial Agents and Chemotherapy and numerous other editorial and advisory boards. He completed undergraduate work at Pepperdine University and his Doctor of Pharmacy (PharmD) from the University of California San Francisco (UCSF), completed at residency at UCSF, and a fellowship in infectious diseases at Hartford Hospital.

Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum

René Russo, PharmD, BCPS

René Russo, PharmD, BCPS

Roger J. Pomerantz, M.D., F.A.C.P.

Christine Ann Miller

Graham G. Lumsden

Marco Taglietti, M.D.

Ankit Mahadevia

Jeffrey Stein, Ph.D.

Evan Loh, M.D.

Michael Dunne, M.D

Ciara Kennedy, Ph.D.

Ted Schroeder

Kevin Finney

Manos Perros, Ph.D.

David Roblin

Stephen Conafay

Christopher J. Burns, Ph.D.

Michael N. Dudley, Pharm.D.

Ramani Varanasi

Corey Fishman

Felix Faupel

Adrian Nivoliez